Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP03…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
TTradingKey | ||
TTradingKey | ||
TTradingKey | ||
CCash | ||
Eckert & Ziegler SE (XTER:EUZ) Q1 2026 Earnings Call Highlights: Strong Medical Division ... Eckert & Ziegler SE (XTER:EUZ) reports a 7% sales increase, driven by a robust medical division, while facing currency impacts and revenue declines in the isotope segment. | ||
3 European Penny Stocks With Market Caps Under €600M The European stock market has recently experienced a positive shift, with the STOXX Europe 600 Index climbing by 3.92% amid hopes for a resolution to Middle East tensions. As investors navigate these fluctuating conditions, penny stocks—often smaller or newer companies—remain an intriguing area of exploration. Despite being an older term, penny stocks can present unique opportunities when they possess strong financials and growth potential, offering investors the chance to uncover hidden... | ||
Molecular Partners Highlights Favorable MP0712 DLL3 Radiotherapeutic Imaging, U.S. Phase I/II Ready Molecular Partners (NASDAQ:MOLN) hosted a webcast to discuss clinical imaging and dosimetry data for MP0712, its DLL3-targeting radiotherapeutic program, following a presentation at the Theranostics World Conference in South Africa. Company executives said the data came from a named patient access p | ||
Molecular Partners AG (VTX:MOLN) is definitely on the radar of hedge funds investors who own 50% of the company Key Insights Given the large stake in the stock by institutions, Molecular Partners' stock price might be vulnerable to... | ||